Teva Pharmaceuticals USA, Inc. Sustainability Profile
Teva Pharmaceuticals USA, Inc., a leading global pharmaceutical company, is headquartered in the United States and operates extensively across North America. Founded in 1901, Teva has established itself as a key player in the pharmaceutical industry, focusing on generic and specialty medications. The company is renowned for its diverse portfolio, which includes a wide range of therapeutic areas such as central nervous system disorders, respiratory conditions, and oncology. Teva's commitment to innovation is evident in its development of unique formulations and delivery systems, setting it apart in a competitive market. With a strong market position, Teva has achieved notable milestones, including being one of the largest generic drug manufacturers worldwide. The company's dedication to improving patient access to essential medications underscores its pivotal role in the healthcare landscape.
DitchCarbon Score
How does Teva Pharmaceuticals USA, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Teva Pharmaceuticals USA, Inc.'s score of 82 is higher than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Teva Pharmaceuticals USA, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. The company is a current subsidiary of Teva Pharmaceutical Industries Limited, which may influence its climate commitments and emissions reporting. Teva Pharmaceutical Industries Limited, as the parent organisation, has set various climate initiatives and targets that cascade down to Teva Pharmaceuticals USA, Inc. These initiatives include participation in the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), both of which aim to enhance transparency and accountability in emissions reduction efforts. However, specific reduction targets or achievements for Teva Pharmaceuticals USA, Inc. have not been disclosed. As part of its commitment to sustainability, Teva Pharmaceuticals USA, Inc. aligns with broader industry standards and practices, although detailed metrics on emissions or specific reduction goals are not currently available. The absence of direct emissions data highlights the need for ongoing efforts in climate accountability and transparency within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Scope 1 | 438,420,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 613,541,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | - | - | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Teva Pharmaceuticals USA, Inc.'s Industry?
How Carbon Intensive is Teva Pharmaceuticals USA, Inc.'s Location?
Teva Pharmaceuticals USA, Inc.'s Scope 3 Categories Breakdown
Teva Pharmaceuticals USA, Inc.'s Scope 3 emissions, which decreased by 6% last year and decreased by approximately 24% since 2020, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 61% of Scope 3 emissions.
Top Scope 3 Categories
Teva Pharmaceuticals USA, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Teva Pharmaceuticals USA, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
